Treatment-resistant depression - An update;Die therapieresistente depression: Ein update

Nervenheilkunde

Volumn 24, Issue 4, 2005, Pages 317-321

  Kaschka, W P ^a   Jandl, M ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

Antidepressants; Augmentation; Neuroplasticity; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Treatment resistant depression

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LAMOTRIGINE; LITHIUM; METYRAPONE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PINDOLOL; PRAMIPEXOLE; PSYCHOSTIMULANT AGENT; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DISEASE CLASSIFICATION; DRUG MONITORING; EVIDENCE BASED MEDICINE; HUMAN; PATHOGENESIS; REVIEW;

EID: 21044444731     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629959     Document Type: Review

References (60)

1. Burrows GD, Norman TR, Judd FK. Definition and differential diagnosis of treatment-resistant depression. Int Clin Psychopharmacol 1994; (Suppl. 2): 5-10.
2. Kaschka WP, König F. Die therapieresistente Depression. In: Kaschka WP (Hrsg). Neurobiologische Forschung und psychiatrische Therapie. Basel: Karger 1996: 116-30.
3. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O et al. Treatment resistant depression: Methodological overview and operational criteria. Eur Neuropsychopharmacol 1999; 9: 83-91.
4. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200.
5. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-59.
6. Möller H-J, Bauer M. Sogenannte therapieresistente Depressionen. In: Riederer P, Laux G, Pöldinger W (Hrsg). Neuro-Psychopharmaka. Ein Therapie-Handbuch. 2. Aufl., Band 3. Wien: Springer 2002; 680-90.
7. Thase ME, Rush AJ. When at first you don't succeed: Sequential strategies for antidepressant non-responders. J Clin Psychiatry 1997; 58(Suppl 13): 23-9.
8. Trivedi MH, Rush AJ, Pan JY, Carmody TJ. Which depressed patients respond to nefazodone and when? J Clin Psychiatry 2001; 62: 158-63.
9. Rush AJ, Batey SR, Donahue RM, Ascher JA, Carmody T, Metz A. Does pretreatment anxiety predict response to either bupropion SR or sertraline? J Affect Disord 2001; 64: 81-7.
10. Rush AJ, Thase ME, Dube' S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry 2003; 53: 743-53.
11. Nierenberg AA, Alpert JE. Depressive breakthrough. Psychiatr Clin North Am 2000; 23: 731-42.
12. Fava M, Kaji J. Continuation and maintenance treatments of major depressive disorder. Psychiatr Ann 1994; 24: 281-90.
13. Rigal JG, Albin HC, Duchier AR, D'Aulnay JM, Fenelon JH, Vincon GA et al. Imipramine blood levels and clinical outcome. J Clin Psychopharmacol 1987; 7: 222-9.
14. Rao ML, Deister A, Laux G, Staberock U, Hoflich G, Möller HJ. Low serum levels of tricyclic antidepressants in amitriptyline- and Doxepin-treated inpatients with depressive syndromes are associated with nonresponse. Pharmacopsychiatry 1996; 29: 97-102.
15. Mörike K, Schwab M. Das Cytochrom-P450-Enzymsystem und seine Bedeutung für den Arzneimittelstoffwechsel. In: König F, Kaschka WP (Hrsg). Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. 2. Aufl. Stuttgart: Thieme 2003; 4-18.
16. König F, Kaschka WP (Hrsg). Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. 2. Aufl. Stuttgart: Thieme 2003.
17. Hiemke C, Härtter S, Weigmann H. Evidence Based Medicine. Therapeutisches Drug Monitoring von Psychopharmaka. Neurotransmitter 2000; 11: 52-5.
18. Lohmann PL, Grasmäder K, Rao ML, Hiemke C. Pharmakokinetik und Pharmakogenetik in der Psychiatrie. Psycho 2002; 28: 534-8.
19. Baumann P, Zullino DF, Jaquenoud Sirot E, Paus E, Eap CB. Therapy with antidepressants: Pharmacogenetic aspects. In: Kaschka WP (ed). Perspectives in affective disorders. Advances in Biological Psychiatry. Vol. 21. Basel: Karger 2002; 95-111.
20. Möller HJ (Hrsg). Therapieresistenz unter Antidepressiva-Behandlung. Berlin, Heidelberg, New York, Tokyo: Springer 1990.
21. Fagiolini A, Kupfer DJ. Is treatment-resistant depression a unique subtype of depression? Biol Psychiatry 2003; 53: 640-8.
22. Rothschild AJ. Challenges in the treatment of depression with psychotic features. Biol Psychiatry 2003; 53: 680-90.
23. Rothenhäusler H-B, Kapfhammer HP. Depression bei körperlichen Erkrankungen - Diagnose und Therapie vor konsiliarpsychiatrischem Hintergrund. Fortschr Neurol Psychiat 2003; 71: 358-65.
24. Arolt V, Rothermundt M. Depressive Störungen bei körperlich Kranken. Nervenarzt 2003; 74: 1033-54.
25. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner J, Gerlach M, Kuss J-J, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-65.
26. Schmauss M, Kapfhammer MP, Meyer P, Hoff P. Combined MAO-inhibitor and tri(tetra)cyclic antidepressant treatment in therapy-resistant depression. Progr Neuro-Psychopharmacol Biol Psychiatr 1988; 12: 523-32.
27. Schmauss M, Messer T. Kombinationstherapie tri(tetra-)zyklischer Antidepressiva mit MAO-Hemmern. In: König F, Kaschka WP (Hrsg). Interaktionen und Wirkmechanismen ausgewählter Psychopharmaka. 2. Aufl. Stuttgart: Thieme 2003; 125-35.
28. De Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug nonresponders. Br J Psychiatry 1981; 138: 252-6.
29. Ebert D, Jaspert A, Murata H, Kaschka WP. Initial lithium augmentaiton improves the antidepressant effects of standard TCA treatment in non-resistant depressed patients. Psychopharmacology (Berl) 1995; 118: 223-5.
30. Kaschka WP. Klinik der Lithiumbehandlung. In: Riederer P, Laux G, Pöldinger W (Hrsg). Neuro-Psychopharmaka. Ein Therapie-Handbuch. 2. Aufl., Bd. 3. Wien: Springer 2002; 815-62.
31. Berger M, van Calker D. Affektive Störungen. In: Berger M (Hrsg). Psychische Erkrankungen. Klinik und Therapie. München, Jena: Urban und Fischer 2004; 541-636.
32. Bauer M., Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 1999; 19: 427-34.
33. Aronson R, Offman JJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53: 842-8.
34. Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 2003; 53: 691-700.
35. Normann C. Novel augmentation strategies in depression. World J Biol Psychiatry 2004; 5 (Suppl. 1): 127.
36. Bauer M, Hellweg R, Gräf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology 1998; 18: 444-55.
37. Sasse J, Köberle U, Bschor T, Adli M, Trendelenburg M, Bauer M. Bipolare Depression: L-Thyroxin-Augmentation als Möglichkeit einer medikamentösen Behandlung. Psychoneuro 2003; 29: 400-2.
38. Dietzfelbinger T, Möller HJ, Steinmeyer EM, Fimmers R. Elektrokrampftherapie als Ultima ratio bei Antidepressiva-Nonrespondern. In: Möller HJ (Hrsg). Therapieresistenz unter Antidepressiva-Behandlung. Berlin, Heidelberg: Springer 1990; 167-85.
39. Kuhs H. Stufen der Behandlungsresistenz bei depressiven Störungen, definiert nach somato-therapeutischen Verfahren. Nervenarzt 1995; 66: 561-7.
40. Kosel M, Schlaepfer TE. Beyond the treatment of epilepsy: new applications of vagus nerve stimulation in psychiatry. CNS Spectr 2003; 8: 515-21.
41. Carpenter LL, Friehs GM, Price LH. Cervical vagus nerve stimulation for treatment-resistant depression. Neurosurg Clin N Am 2003; 14: 275-82.
42. Bolwig TG. Putative common pathways in therapeutic brain stimulation in affective disorders. CNS Spectr 2003; 8: 490-5.
43. Manji H, Quiroz JA, Sporn J, Payne JL, Denicoff K, Gray NA, Zarate CA, Charney DS. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 2003; 53: 707-42.
44. Hinze-Selch D, Koch JM, Aldenhoff JB. Die Bedeutung neurotropher Faktoren für die Depression und ihre Therapie. Nervenheilkunde 2002; 21: 497-501.
45. Lieb K, Herpfer J, Fiebich L, Berger M. Substanz P und Substanz-P-Rezeptorantagonisten in der Pathogenese und Therapie affektiver Störungen. Nervenheilkunde 2002; 21: 493-6.
46. Taylor WD, Steffens DC, Mac Fall JR, Mc Quoid DR, Payne ME, Provenzale JM, Krishnan KRR. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003; 60: 1090-6.
47. Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 1993; 33: 181-214.
48. Bowden CL, Calabrese JR, Sachs G, Yatham LN, Asghar SA, Hompland M, Montgomery P, Earl N, Smoot TM, De Veaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400.
49. Bauer MS, Mitchner L. What is a "mood stabilizer"? An evidence-based response. Am J Psychiatry 2004; 161: 3-18.
50. Calabrese JR, Bowden CL, Sachs G, Yatham LN, Behnke K, Mehtonen O-P, Montgomery P, Ascher J, Paska W, Earl N, De Veaugh-Geiss J. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-24.
51. Schlaepfer TE, Lisanby HS, Fisch H-U, Sackeim HA. Magnetic seizure induction for the treatment of major depression. European Psychiatry 2002; 17: 43s (Abstract)
52. Menza MA, Kaufman KR, Castellanos AM. Modafinil augmentation of antidepressant treatment in depression. J Clin Psychiatry 2000; 61: 378-81.
53. Bodkin JA, Lasser RA, Wines J-DJ, Gardner DM et al. Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. J Clin Psychiatry 1997; 58: 137-45.
54. th Annual Meeting of the American Psychiatric Association, San Francisco 1993.
55. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001; 158: 131-4.
56. Petersen T, Papakostas GI, Mahal Y, Guyker WM, Beaumont EC, Alpert JE, Fava M, Nierenberg AA. Psychosocial functioning in patients with treatment resistant depression. European Psychiatry 2004; 19: 196-201.
57. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004; 161: 564-6.
58. Pfeiffer H, Scherer J, Albus M. L-Thyroxin-Hochdosierung bei therapieresistenter Depression. Nervenarzt 2004; 75: 242-8.
59. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003; 301: 805-9.
60. Zarate jr. CA, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004; 56: 54-60.